Company Description
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi‑R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim‑R, a proprietary synthetic-cell mimetic.
It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications.
Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 300 |
| CEO | Lynn Seely |
Contact Details
Address: 201 Haskins Way South San Francisco, California 94080 United States | |
| Phone | (650) 695-0677 |
| Website | lyell.com |
Stock Details
| Ticker Symbol | LYEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001806952 |
| CUSIP Number | 55083R203 |
| ISIN Number | US55083R2031 |
| Employer ID | 83-3006753 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lynn Seely M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Richard D. Klausner M.D. | Founder and Executive Chairman |
| Stephen J. Hill | Chief Operating Officer |
| Matthew Lang J.D. | Advisor |
| Prof. Stanley R. Riddell M.D. | Founder and Scientific Advisor |
| Dr. Crystal L. Mackall M.D. | Founder and Scientific Advisor |
| Charles W. Newton | Chief Financial Officer |
| Nellie Dillery | Director of Accounting |
| Dr. Gary Lee Ph.D. | Chief Scientific Officer |
| Ellen Rose | Senior Vice President of Communications and Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 1, 2025 | SCHEDULE 13G | Filing |
| Jul 31, 2025 | 424B5 | Filing |
| Jul 30, 2025 | EFFECT | Notice of Effectiveness |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 18, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 8-K | Current Report |